Tissue | Expression Dynamics | Abbreviation |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/RIPK1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/RIPK1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/RIPK1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/RIPK1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:20012387 | Endometrium | AEH | positive regulation of extrinsic apoptotic signaling pathway | 15/2100 | 48/18723 | 1.58e-04 | 2.08e-03 | 15 |
GO:19900007 | Endometrium | AEH | amyloid fibril formation | 12/2100 | 34/18723 | 1.97e-04 | 2.49e-03 | 12 |
GO:200123716 | Endometrium | AEH | negative regulation of extrinsic apoptotic signaling pathway | 23/2100 | 97/18723 | 3.66e-04 | 3.99e-03 | 23 |
GO:190370614 | Endometrium | AEH | regulation of hemopoiesis | 63/2100 | 367/18723 | 3.81e-04 | 4.10e-03 | 63 |
GO:190320110 | Endometrium | AEH | regulation of oxidative stress-induced cell death | 19/2100 | 74/18723 | 4.00e-04 | 4.28e-03 | 19 |
GO:004563716 | Endometrium | AEH | regulation of myeloid cell differentiation | 40/2100 | 210/18723 | 5.49e-04 | 5.52e-03 | 40 |
GO:003647315 | Endometrium | AEH | cell death in response to oxidative stress | 22/2100 | 95/18723 | 6.87e-04 | 6.62e-03 | 22 |
GO:007135610 | Endometrium | AEH | cellular response to tumor necrosis factor | 41/2100 | 229/18723 | 1.66e-03 | 1.36e-02 | 41 |
GO:003009916 | Endometrium | AEH | myeloid cell differentiation | 62/2100 | 381/18723 | 1.67e-03 | 1.36e-02 | 62 |
GO:190040710 | Endometrium | AEH | regulation of cellular response to oxidative stress | 20/2100 | 89/18723 | 1.74e-03 | 1.40e-02 | 20 |
GO:00321036 | Endometrium | AEH | positive regulation of response to external stimulus | 68/2100 | 427/18723 | 1.82e-03 | 1.44e-02 | 68 |
GO:003461210 | Endometrium | AEH | response to tumor necrosis factor | 44/2100 | 253/18723 | 2.08e-03 | 1.61e-02 | 44 |
GO:19032092 | Endometrium | AEH | positive regulation of oxidative stress-induced cell death | 7/2100 | 18/18723 | 2.29e-03 | 1.74e-02 | 7 |
GO:00510905 | Endometrium | AEH | regulation of DNA-binding transcription factor activity | 69/2100 | 440/18723 | 2.51e-03 | 1.87e-02 | 69 |
GO:00332098 | Endometrium | AEH | tumor necrosis factor-mediated signaling pathway | 21/2100 | 99/18723 | 2.87e-03 | 2.05e-02 | 21 |
GO:00328743 | Endometrium | AEH | positive regulation of stress-activated MAPK cascade | 25/2100 | 126/18723 | 3.18e-03 | 2.24e-02 | 25 |
GO:00703044 | Endometrium | AEH | positive regulation of stress-activated protein kinase signaling cascade | 25/2100 | 128/18723 | 3.95e-03 | 2.65e-02 | 25 |
GO:00456398 | Endometrium | AEH | positive regulation of myeloid cell differentiation | 21/2100 | 103/18723 | 4.69e-03 | 2.99e-02 | 21 |
GO:00018198 | Endometrium | AEH | positive regulation of cytokine production | 71/2100 | 467/18723 | 4.76e-03 | 3.02e-02 | 71 |
GO:00703015 | Endometrium | AEH | cellular response to hydrogen peroxide | 20/2100 | 98/18723 | 5.64e-03 | 3.46e-02 | 20 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0513126 | Endometrium | AEH | Shigellosis | 78/1197 | 247/8465 | 9.23e-13 | 2.00e-11 | 1.46e-11 | 78 |
hsa0513226 | Endometrium | AEH | Salmonella infection | 71/1197 | 249/8465 | 1.69e-09 | 3.44e-08 | 2.52e-08 | 71 |
hsa0513026 | Endometrium | AEH | Pathogenic Escherichia coli infection | 50/1197 | 197/8465 | 1.72e-05 | 1.86e-04 | 1.36e-04 | 50 |
hsa0516924 | Endometrium | AEH | Epstein-Barr virus infection | 42/1197 | 202/8465 | 5.72e-03 | 3.05e-02 | 2.23e-02 | 42 |
hsa0421010 | Endometrium | AEH | Apoptosis | 30/1197 | 136/8465 | 7.72e-03 | 4.05e-02 | 2.96e-02 | 30 |
hsa0517018 | Endometrium | AEH | Human immunodeficiency virus 1 infection | 43/1197 | 212/8465 | 8.19e-03 | 4.22e-02 | 3.09e-02 | 43 |
hsa0516320 | Endometrium | AEH | Human cytomegalovirus infection | 45/1197 | 225/8465 | 8.98e-03 | 4.56e-02 | 3.34e-02 | 45 |
hsa05131111 | Endometrium | AEH | Shigellosis | 78/1197 | 247/8465 | 9.23e-13 | 2.00e-11 | 1.46e-11 | 78 |
hsa05132112 | Endometrium | AEH | Salmonella infection | 71/1197 | 249/8465 | 1.69e-09 | 3.44e-08 | 2.52e-08 | 71 |
hsa05130112 | Endometrium | AEH | Pathogenic Escherichia coli infection | 50/1197 | 197/8465 | 1.72e-05 | 1.86e-04 | 1.36e-04 | 50 |
hsa05169111 | Endometrium | AEH | Epstein-Barr virus infection | 42/1197 | 202/8465 | 5.72e-03 | 3.05e-02 | 2.23e-02 | 42 |
hsa0421015 | Endometrium | AEH | Apoptosis | 30/1197 | 136/8465 | 7.72e-03 | 4.05e-02 | 2.96e-02 | 30 |
hsa0517019 | Endometrium | AEH | Human immunodeficiency virus 1 infection | 43/1197 | 212/8465 | 8.19e-03 | 4.22e-02 | 3.09e-02 | 43 |
hsa05163110 | Endometrium | AEH | Human cytomegalovirus infection | 45/1197 | 225/8465 | 8.98e-03 | 4.56e-02 | 3.34e-02 | 45 |
hsa0513127 | Endometrium | EEC | Shigellosis | 79/1237 | 247/8465 | 1.80e-12 | 3.95e-11 | 2.95e-11 | 79 |
hsa0513227 | Endometrium | EEC | Salmonella infection | 71/1237 | 249/8465 | 7.11e-09 | 1.30e-07 | 9.69e-08 | 71 |
hsa0513027 | Endometrium | EEC | Pathogenic Escherichia coli infection | 51/1237 | 197/8465 | 1.98e-05 | 2.28e-04 | 1.70e-04 | 51 |
hsa0516925 | Endometrium | EEC | Epstein-Barr virus infection | 47/1237 | 202/8465 | 6.17e-04 | 4.41e-03 | 3.29e-03 | 47 |
hsa0516325 | Endometrium | EEC | Human cytomegalovirus infection | 47/1237 | 225/8465 | 6.17e-03 | 3.12e-02 | 2.33e-02 | 47 |
hsa046687 | Endometrium | EEC | TNF signaling pathway | 27/1237 | 114/8465 | 6.47e-03 | 3.22e-02 | 2.40e-02 | 27 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RIPK1 | SNV | Missense_Mutation | | c.1237N>T | p.Arg413Cys | p.R413C | Q13546 | protein_coding | deleterious(0) | probably_damaging(0.925) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RIPK1 | SNV | Missense_Mutation | | c.919G>C | p.Glu307Gln | p.E307Q | Q13546 | protein_coding | tolerated(0.52) | benign(0.003) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
RIPK1 | SNV | Missense_Mutation | | c.808N>T | p.Ala270Ser | p.A270S | Q13546 | protein_coding | tolerated(0.38) | benign(0.173) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
RIPK1 | SNV | Missense_Mutation | novel | c.1281N>C | p.Glu427Asp | p.E427D | Q13546 | protein_coding | tolerated(0.41) | benign(0) | TCGA-C8-A132-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RIPK1 | SNV | Missense_Mutation | | c.439N>A | p.Asp147Asn | p.D147N | Q13546 | protein_coding | deleterious(0.03) | probably_damaging(0.987) | TCGA-E2-A152-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | PD |
RIPK1 | insertion | Frame_Shift_Ins | novel | c.1407_1408insGGTCCTGTGGAGGAGTCCTGGTTTGCTCCTTCCCTGG | p.Ser470GlyfsTer42 | p.S470Gfs*42 | Q13546 | protein_coding | | | TCGA-A8-A092-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR |
RIPK1 | SNV | Missense_Mutation | | c.324N>C | p.Met108Ile | p.M108I | Q13546 | protein_coding | tolerated(0.62) | benign(0) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
RIPK1 | SNV | Missense_Mutation | | c.1297G>A | p.Glu433Lys | p.E433K | Q13546 | protein_coding | tolerated(0.79) | benign(0.021) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
RIPK1 | SNV | Missense_Mutation | rs748885856 | c.1571N>T | p.Pro524Leu | p.P524L | Q13546 | protein_coding | tolerated(0.12) | benign(0) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
RIPK1 | deletion | Frame_Shift_Del | novel | c.1302delN | p.Gly436AlafsTer76 | p.G436Afs*76 | Q13546 | protein_coding | | | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8737 | RIPK1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 340590273 | | |
8737 | RIPK1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 249565867 | | |
8737 | RIPK1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 178102513 | PONATINIB | |
8737 | RIPK1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 384403680 | | |
8737 | RIPK1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | RESVERATROL | RESVERATROL | 16116226 |
8737 | RIPK1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 336446940 | | |
8737 | RIPK1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 354702223 | NECROSTATIN | |
8737 | RIPK1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | GSK2982772 | | |
8737 | RIPK1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 354702224 | | |
8737 | RIPK1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 354702222 | | |